Generative AI medical devices: FDA asks for feedback by 19 October

Disclosure: The operator of this site provides engineering services in regulatory affairs for medical devices.

What happened: On 18 August 2026, FDA published a discussion paper on medical devices that use generative AI. Comments are open until 19 October 2026 (docket FDA-2026-N-7874). It matters what the paper is not: FDA states explicitly that it is neither draft nor final guidance. It is a basis for discussion.

The problem: Generative AI, meaning models that produce text or images, is hard to test with the classic “known input, expected output” approach. Answers vary, the model can state wrong things convincingly, and the underlying foundation model often comes from a third party that keeps changing it.

What FDA proposes (according to an analysis by Cooley dated 28 September):

• Risk on two axes: How autonomously does the device act, and how serious is an error if someone relies on its output? Patient-facing functions are treated as higher risk than those aimed at clinicians.
• Assessment like a professional’s: First, non-clinical benchmarking across defined competency areas such as domain knowledge, safety behaviour and generalisability. Then clinical validation, scaled to risk, ranging from retrospective data to randomised trials.
• Postmarket monitoring: Repeated benchmarks, spot checks by clinicians and monitoring for performance degradation (“drift”).
• Foundation model master files: Providers of foundation models could file confidential information with FDA for manufacturers to reference. This would not amount to clearing the foundation model itself.

What manufacturers can do now:

1. Place the device on both axes and document the reasoning.
2. Build a benchmark set with acceptance criteria that can be rerun later.
3. Review contracts with foundation model providers: can a model version be pinned, and will you be told about changes?
4. Plan postmarket monitoring from the start, not after clearance.
5. Submit your own experience through the FDA docket by 19 October.

Context: The direction is visible, but nothing is binding yet. Anyone planning today should treat the proposals as a likely yardstick, not as a current requirement.

Source: Considerations for the Regulation of Generative AI-Enabled Medical Devices: Discussion Paper and Request for Feedback (FDA), of 18 Aug 2026